ABSTRACT
Cystic fibrosis is caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, and the predominant mutation is termed Phe508del (F508del). Therapy for F508delCFTR patients is based on the use of Orkambi®, a combination of VX809 and VX770. However, though Orkambi leads to an improvement in the lung function of patients, a progressive reduction in its efficacy has been observed. In order to overcome this effect, the aim of the present study was to investigate the role of matrine and the inhouse compound FD2 in increasing the action of VX809 and VX770. Fischer rat thyroid cells overexpressing F508delCFTR were treated with matrine, VX809 (corrector) and/or with a number of potentiators (VX770, FD1 and FD2). The results demonstrated that matrine was able to stimulate CFTR activity and, in association with FD2, increased the functionality of the channel in the presence of VX809. Based on these results, it may be hypothesized that FD2 may be a novel and more effective potentiator compared with VX770.
Subject(s)
Alkaloids/pharmacology , Alleles , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Ethanolamines/pharmacology , Mutation , Phenyl Ethers/pharmacology , Quinolizines/pharmacology , Animals , Cell Line , Cell Survival/drug effects , Cystic Fibrosis/genetics , Cystic Fibrosis/metabolism , Drug Synergism , Ion Channel Gating/drug effects , Rats , MatrinesABSTRACT
The phenylhydrazone RDR-1 is endowed with moderate activity as F508del-CFTR corrector; nevertheless, its simple structure enables stimulating developments in this class of correctors. Therefore, we synthesized a number of phenylhydrazones 3 by reacting phenylhydrazine derivatives 1 with furfural derivatives 2. By the same reaction, also the pyridine derivatives 4, the thiophene derivatives 5, and the hydrazides 6 and 7 were prepared. All compounds were tested as F508del-CFTR correctors in the cystic fibrosis (CF) bronchial epithelial cell line CFBE41o-, using corr-4a and VX-809 as controls. Some of the tested compounds emerged as interesting F508del-CFTR correctors at 20 µM (3c) and 2 µM (5d). 3c and 5d administered together with VX-809 produced a satisfactory additivity of action. When the structure of 5d was overlapped with RDR-1 and five other established correctors, a shared central design was clearly visible. This fact may be of interest in the search for new F508del-CFTR correctors.
Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Furans/chemistry , Hydrazones/chemistry , Thiophenes/chemistry , Aminopyridines/pharmacology , Benzodioxoles/pharmacology , Cell Line , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Furans/chemical synthesis , Furans/pharmacology , Humans , Hydrazones/chemical synthesis , Hydrazones/pharmacology , Mutation , Structure-Activity Relationship , Thiophenes/chemical synthesis , Thiophenes/pharmacologyABSTRACT
BACKGROUND: The F508del mutation impairs the trafficking of CFTR from endoplasmic reticulum to plasma membrane and is responsible of a severe form of cystic fibrosis. Trafficking can be improved by small organic molecules called 'correctors'. MATERIALS & METHODS: By different synthetic ways, we prepared 4-chloroanisole and 2-(4-chloroanisol-2-yl)aminothiazole derivatives. Such compounds were ineffective as correctors but we could find a sign of activity in an intermediate. In the meantime, we found a common pharmacophoric moiety present in four known correctors. RESULTS: Following this structural indication, we synthesized a small set of new molecules endowed with a significant, even if not great, F508del-CFTR rescue activity. CONCLUSION: The cited structural feature seems interesting in the search of new correctors. To corroborate this observation, later on we found a new pyrazine derivative (Novartis) endowed with a potent activity as corrector and having the cited common design.
Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Vasodilator Agents/chemistry , Anisoles/chemistry , Cystic Fibrosis/drug therapy , Cystic Fibrosis Transmembrane Conductance Regulator/chemistry , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Gene Deletion , Humans , Models, Molecular , Molecular Conformation , Piperazines/chemistry , Purines/chemistry , Pyrazines/chemical synthesis , Pyrazines/chemistry , Pyrazines/therapeutic use , Sildenafil Citrate , Sulfonamides/chemistry , Thiazoles/chemical synthesis , Thiazoles/chemistry , Thiazoles/therapeutic use , Vasodilator Agents/therapeutic useABSTRACT
Cystic fibrosis (CF) is a common inherited fatal disease affecting 70,000 people worldwide, with a median predicted age of survival of approximately 38 years. The deletion of Phenylalanine in position 508 of the Cystic Fibrosis Transmembrane conductance Regulator (F508del-CFTR) is the most common mutation in CF patients: the deleted protein, not properly folded, is degraded. To date no commercial drugs are available. Low temperature, some osmolytes and conditions able to induce heat shock protein 70 (Hsp70) expression and heat shock cognate 70 (Hsc70) inhibition result in F508del-CFTR rescue, hence restoring its physiological function: this review sheds light on the correlation between these several evidences. Interestingly, all these approaches have a role in the cell stress response (CSR), a set of cell reactions to stress. In addition, unpredictably, F508del-CFTR rescue has to be considered in the frame of CSR: entities that induce - or are induced during - the CSR are, in general, also able to correct trafficking defect of CFTR. Specifically, the low temperature induces, by definition, a CSR; osmolytes, such as glycerol and trimethylamine N-oxide (TMAO), are products of the CSR; pharmacological correctors, such as Matrine and 4-phenylbutirric acid (4PBA), down-regulate the constitutive Hsc70 in favor of an up-regulation of the inducible chaperone Hsp70, another component of the CSR. The identification of a common mechanism of action for different types of correctors could drive the discovery of new active molecules in CF, overcoming methods clinically inapplicable, such as the low temperature.